N-苯甲酰基-L-精氨酸甲酯 | 967-88-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-苯甲酰基-L-精氨酸甲酯
• 英文名称: Benzoyl L-arginine methyl ester
• 英文别名: methyl (2S)-2-benzamido-5-(diaminomethylideneamino)pentanoate
• CAS: 967-88-4
• 化学式: C₁₄H₂₀N₄O₃
• 分子量: 292.338
• InChiKey: KAOMIKSYDXLMCD-NSHDSACASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  21
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  120
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 海关编码：
  2925290090

反应信息

• 作为反应物：
  描述：

  N-苯甲酰基-L-精氨酸甲酯 在 氨 作用下， 生成 N-Alpha-苯甲酰-L-精氨酰胺盐酸盐
  参考文献：
  名称：

  Dirr; Spaeth, Hoppe-Seyler's Zeitschrift fur Physiologische Chemie, 1935, vol. 237, p. 121,126

  摘要：

  DOI：
• 作为产物：
  描述：

  苯甲酰氯 在 盐酸 、 水 作用下， 生成 N-苯甲酰基-L-精氨酸甲酯
  参考文献：
  名称：

  Bergmann; Fruton; Pollok, Journal of Biological Chemistry, 1939, vol. 127, p. 643,647

  摘要：

  DOI：

文献信息

• Reactions of osmium tetraoxide with protein side chains and unsaturated lipids
  作者：Alastair J. Nielson、William P. Griffith

  DOI：10.1039/dt9790001084

  日期：——

  The reactions of OsO4 with derivatives or model systems (L) for the side chains of tissue proteins have been studied, alone and in the presence of unsaturated lipids (R). The following new complexes have been isolated and their structures studied by vibrational and 1H n.m.r. spectroscopy: Os2O6L4(L =α-N-benzoyl-L-histidine isobutyl ester, imidazole, 1-methylimidazole, 5,6-dimethylbenzimidazole, n-butylamine

  已经研究了OsO 4与组织蛋白侧链的衍生物或模型系统（L）的反应，这些反应单独或在不饱和脂质（R）存在下进行。已分离出以下新的配合物，并通过振动和1 H nmr光谱研究了其结构：Os 2 O 6 L 4（L =α- N-N-苯甲酰基-L-组氨酸异丁酯，咪唑，1-甲基咪唑，5,6-二甲基苯并咪唑，正丁胺或α- N-苯甲酰基-DL-蛋氨酸）; OsL 2（L =谷胱甘肽或L-半胱氨酸）；混合物种Os 2 O 6 L3 L'（L = 1-甲基咪唑，L'=大号-脯氨酸甲酯或α- ñ -benzoyl-大号精氨酸乙酯）和OsLL' Ñ（L = 1-甲基咪唑，L'=α- ñ -苯甲酰-大号-半胱氨酸或α- ñ乙酰基大号-半胱氨酸）; OsO 2（O 2 R）L 2（R =环己烯，油酸，油酸甲酯或乙酸胆固醇酯； L = 1-甲基-和5,6-二甲基苯并咪唑，α- N-苯甲酰基-L-组氨酸异丁酯或吡啶）；Os
• Cell Permeable Inhibitors of Anaphase Promoting Complex
  申请人：King Randall

  公开号：US20130230458A1

  公开（公告）日：2013-09-05

  The invention provides compositions and methods for treating cell cycle disorders. Compositions of the invention include proTAME, a prodrug analog of TAME, and, optionally, one or more therapeutic agents.

  本发明提供了用于治疗细胞周期紊乱的组合物和方法。本发明的组合物包括proTAME，TAME的前药类似物，以及一个或多个治疗剂（可选）。
• CELL PERMEABLE INHIBITORS OF ANAPHASE PROMOTING COMPLEX
  申请人：President and Fellows of Harvard College

  公开号：US20150328214A1

  公开（公告）日：2015-11-19

  The disclosure provides compositions and methods for treating cell cycle disorders. Compositions of the disclosure include proTAME, a prodrug analog of TAME and apcin, the combination of which inhibits an activity or function of the anaphase promoting complex (APC) by a synergistic mechanism.

  本公开提供了用于治疗细胞周期紊乱的组合物和方法。本公开的组合物包括proTAME和apcin，它们的组合通过协同作用机制抑制负责有丝分裂后期促进复合物（APC）的活性或功能。其中，proTAME是TAME的前药类似物。
• Regulation of mammalian hair growth
  申请人：Oblong Erich John

  公开号：US20050003024A1

  公开（公告）日：2005-01-06

  The present invention relates to a topical skin care composition containing a safe and effective amount of a skin care active comprising agmatine, and its salt; a safe and effective amount of a first additional skin care active selected from the group consisting of BHT or BHA, hexamidine, cetyl pyridinium chloride, green tea catechins, phytosterols, ursolic acid, compounds derived from plant extracts, their salts and derivatives; and a dermatologically acceptable carrier for the agmatine composition. The present invention also relates to methods of using such agmatine compositions to regulate hair growth and the condition of mammalian skin. Said methods generally comprise the step of topically applying the composition to the skin of a mammal needing such treatment, a safe and effective amount of such compositions.

  本发明涉及一种局部皮肤护理组合物，该组合物含有安全有效量的皮肤护理活性物质，该活性物质包括阿matine 及其盐；安全有效量的第一种附加皮肤护理活性物质，该活性物质选自由 BHT 或 BHA、己脒、十六烷基氯化吡啶、绿茶儿茶素、植物甾醇、熊果酸、从植物提取物中提取的化合物、它们的盐和衍生物组成的组；以及皮肤病学上可接受的阿matine 组合物载体。本发明还涉及使用此类琼脂糖组合物调节毛发生长和哺乳动物皮肤状况的方法。所述方法一般包括将组合物局部施用到需要此类治疗的哺乳动物的皮肤上，施用安全有效量的此类组合物。
• Personal care compositions and methods regulating mammalian hair growth
  申请人：Oblong Erich John

  公开号：US20050255060A1

  公开（公告）日：2005-11-17

  Personal care compositions comprising at least one chronic skin care active selected from the group consisting of butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), hexyl isobutyrate, menthyl anthranilate, methofuran, 3-butylidenepthalide, cetyl pyridinium chloride, green tea extract, catechins, phytosterols, ursolic acid, and plant extract compounds; at least one acute skin care active selected from the group consisting of particulate materials (including particles, pigments, and cross-linked silicone elastomers), alkane polyols, panthenol and pantothenic acid derivatives, and tanning actives; and a dermatologically acceptable carrier. The composition can also comprise the cationic thickener, Polyquaternium 37. The present invention also relates to methods of using such compositions to regulate hair growth and the condition of mammalian skin. Said methods generally comprise the step of topically applying the composition to the skin of a mammal needing such treatment, a safe and effective amount of such compositions.

  个人护理组合物，包含至少一种慢性皮肤护理活性物质，该活性物质选自由丁基化羟基甲苯（BHT）、丁基化羟基茴香醚（BHA）、异丁酸己酯、蒽酸薄荷酯、甲氧呋喃、3-丁基亚苯酞、氯化十六烷基吡啶鎓、绿茶提取物、儿茶素、植物甾醇、熊果酸和植物提取物化合物组成的组；至少一种急性皮肤护理活性物质，选自颗粒材料（包括微粒、颜料和交联硅弹性体）、烷烃多元醇、泛醇和泛酸衍生物以及鞣革活性物质组成的组；以及皮肤病学上可接受的载体。该组合物还可以包含阳离子增稠剂聚季铵盐 37。本发明还涉及使用此类组合物调节毛发生长和哺乳动物皮肤状况的方法。所述方法一般包括将组合物局部施用到需要此类治疗的哺乳动物的皮肤上，施用安全有效量的此类组合物。